[Skip to Content]

Upstate Active Clinical Trials

Study Title:

A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon) on Glucose
Control in Patients with Type 1 Diabetes.

What is the purpose of the study?

The aim of this study is to investigate if exenatide can improve the control of glucose in patients with Type 1 diabetes (T1D). We would also like to investigate whether insulin production (in the patients who still produce insulin) can be improved with the study drug Exenatide and if the need for insulin will be lower with exenatide. To be able to actually look for these changes before and after treatment we will need to divide the participants into two groups. One group will receive the actual drug exenatide and the other group will receive placebo. A placebo is an inactive substance that looks like the study medication, but does not have any study medication in it.

Upstate Institutional Review Board (IRB) Number:

726388

Study Phase:

Phase II

Patient Age Group:

Adults

Principal Investigator:

Ruth S Weinstock, MD, PhD

Who can I contact for more information?

Name: Suzan M Bzdick, RN
Phone: 315-464-9006
Email: bzdicks@upstate.edu

Return to Previous Page || Search Again

Top